Trade Mark Journal No.2025/032 8 August 2025

UK00004241786 30 July 2025 (5)

HARTCIMO

International priority date claimed: 24 February 2025 (United States of America) (99053903)

Class 5: Pharmaceutical preparations for human use, namely, medications to treat cardiovascular conditions; pharmaceutical preparations to treat hypertrophic cardiomyopathies, heart failure, and heart failure with preserved ejection fraction.

Cytokinetics, Incorporated

Representative: Finnegan Europe LLP